Evidence map›Paper›PMID 39417944›Full record

ArticleBlood research2024

Prognostic significance and biological implications of SM-like genes in mantle cell lymphoma.

Xue He, Changjian Yan, Yaru Yang, Weijia Wang, Xiaoni Liu, Chaoling Wu, Zimu Zhou, Xin Huang, Wei Fu, Jing Hu and 11 more

Abstract read
In one paragraph

Article in Blood research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Xue He *Department of Pathology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
Changjian Yan *Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, 100191, China.
Yaru Yang *The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Weijia Wang *Department of Pathology, The First Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
Xiaoni LiuDepartment of Respiratory Medicine, The First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, China.
Chaoling WuDepartment of Respiratory Medicine, Affiliated Hospital of Jiujiang University, Jiujiang, 332000, China.
Zimu ZhouGannan Medical University, Ganzhou, 341000, China.
Xin HuangDepartment of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, 100191, China.
Wei FuDepartment of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, 100191, China.
Jing HuDepartment of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, 100191, China.
Ping YangDepartment of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, 100191, China.
Jing WangDepartment of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, 100191, China.
Mingxia ZhuDepartment of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, 100191, China.
Yan LiuDepartment of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, 100191, China.
Wei ZhangDepartment of Pathology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
Shaoxiang LiDepartment of Pathology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
Gehong DongDepartment of Pathology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
Xiaoliang YuanDepartment of Respiratory Medicine, The First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, China.
Yuansheng LinDepartment of Intensive Care Unit, Suzhou Research Center of Medical School, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, Suzhou, 215000, China. linys202012@163.com.
Hongmei JingDepartment of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, 100191, China. hongmeijing@bjmu.edu.cn.
Weilong ZhangDepartment of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, 100191, China. zhangwl2012@126.com.

Funding

China Health Promotion Foundation CHPF-zlkysx-001Educational Commission of Jiangxi Province, China. GJJ14676Health Commission of Jiangxi Province, and Science and Technology Research Foundation 20141114Key Clinical Projects of Peking University Third Hospital BYSYZD2019026National Natural Science Foundation of China 81800195Natural Science Foundation of Beijing Municipality 7182178Wu Jieping Medical Foundation 320.6750
6 · The paper itself

Abstract

backgroundSM-like (LSM) genes a family of RNA-binding proteins, are involved in mRNA regulation and can function as oncogenes by altering mRNA stability. However, their roles in B-cell progression and tumorigenesis remain poorly understood.

methodsWe analyzed gene expression profiles and overall survival data of 123 patients with mantle cell lymphoma (MCL). The LSM index was developed to assess its potential as a prognostic marker of MCL survival.

resultsFive of the eight LSM genes were identified as potential prognostic markers for survival in MCL, with particular emphasis on the LSM.index. The expression levels of these LSM genes demonstrated their potential utility as classifiers of MCL. The LSM.index-high group exhibited both poorer survival rates and lower RNA levels than did the overall transcript profile. Notably, LSM1 and LSM8 were overexpressed in the LSM.index-high group, with LSM1 showing 2.5-fold increase (p < 0.001) and LSM8 depicting 1.8-fold increase (p < 0.01) than those in the LSM.index-low group. Furthermore, elevated LSM gene expression was associated with increased cell division and RNA splicing pathway activity.

conclusionsThe LSM.index demonstrates potential as a prognostic marker for survival in patients with MCL. Elevated expression of LSM genes, particularly LSM1 and LSM8, may be linked to poor survival outcomes through their involvement in cell division and RNA splicing pathways. These findings suggest that LSM genes may contribute to the aggressive behavior of MCL and represent potential targets for therapeutic interventions.

Indexed as

LSM1LSM8LSM genesMantle cell lymphomaRNA degradation

Identifiers

PMID39417944
PMCPMC11486876

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.